Stock Rating Report for AMLN

Ticker: 

Stock Information

Ticker AMLN
Company Name Amylin Pharmaceuticals, Inc
Current Price $16.89
Previous Close $16.89
Industry Biotechnology
Sector HEALTHCARE
Long Stop Loss Members Only
Short Stop Loss Members Only
Expected Move Members Only
Optionable? Yes

StockProphet Ratings

Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.

Sector Risks

Sign up for MarketProphet today to see our 30, 60, and 90 day risk assessment for this stock.


Chart

We use technical analysis and fundamental analysis to recommend ratings for thousands of stocks. If you had a subscription, this space would show our 3 year history of trades for AMLN. However, we only show it to our subscribers.

We update our ratings and stop losses EVERY WEEK.

Don't miss out on what we recommend for Amylin Pharmaceuticals, Inc next week. Sign up today and start making money!

Demand Fundamentals

Demand Fundamental Value Score Rating
Qtr/Qtr Revenue Growth Members Only
Qtr/Qtr Earnings Growth Members Only
Year/Year Revenue Growth Members Only
Year/Year Earnings Growth Members Only
Multi-Year Revenue Growth Members Only
Multi-Year Earnings Growth Members Only
Relative PE Ranking Members Only
Return on Equity Members Only
Yield Members Only
Institutional Holding Members Only
Stock Price Members Only
Relative Fundamental Ranking Members Only
Total Score Members Only

Demand Technicals

Demand Technical Value Score Rating
Recommended Condition Members Only
Trading Zone Members Only
Average Trading Volume Members Only
Industry Bull/Bear Condition Members Only
Sector Bull/Bear Condition Members Only
Current Signal Start Date Members Only
Total Score Members Only

Company Profile

Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases. The company's products include BYETTA (exenatide) injection for the treatment of type 2 diabetes- and SYMLIN (pramlintide acetate) injection for the treatment of type 1 and type 2 diabetes. Its late stage development program in diabetes consists of BYDUREON (exenatide extended-release for injectable suspension), an investigational sustained-release medication for type 2 diabetes that is administered once a week. The company's obesity development program primarily focuses on two molecular franchises, including pramlintide, a synthetic amylin analog- and metreleptin, a recombinant leptin analog. It is developing pramlintide/metreleptin combination therapy, which is a product candidate in phase 2 for the treatment of obesity. The company markets its products to healthcare providers, managed healthcare organizations, wholesalers and pharmacies, government purchasers, and other third-party payers primarily in the United States. It has collaboration agreements with Eli Lilly and Company- Alkermes, Inc.- Takeda Pharmaceutical Company Limited- Biocon, Ltd.- and Juvenile Diabetes Research Foundation International Inc. The company was founded in 1987 and is based in San Diego, California.


Latest News

Tue, 07 Feb 2012 21:20:00 GMT[video] Analyst Moves: AMLN, HCA
Tue, 07 Feb 2012 21:01:26 GMTAnalyst Moves: AMLN, HCA
Tue, 07 Feb 2012 19:03:37 GMTTake the Long Road with Alkermes
Tue, 07 Feb 2012 14:57:08 GMTGappers report: Bullish gaps
Tue, 07 Feb 2012 14:30:44 GMTNew Star Analyst Rankings for Amylin Pharmaceuticals, Inc.
Tue, 07 Feb 2012 14:24:56 GMTPre-market top 5 gainers
Tue, 07 Feb 2012 14:21:16 GMTAnalysts' Actions: IBM, AON, FOSL, HUM, EMC
Tue, 07 Feb 2012 12:04:29 GMTAmylin price target raised to $30 from $25 at Jefferies
Tue, 07 Feb 2012 01:50:04 GMTAmylin Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript
Tue, 07 Feb 2012 00:57:58 GMTAmylin takes 4Q loss as Lilly partnership ends
Mon, 06 Feb 2012 21:58:56 GMTAMYLIN PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
Mon, 06 Feb 2012 14:42:47 GMT5 of Last Week's Biggest Winners
Mon, 06 Feb 2012 14:30:22 GMTNovo Nordisk Posts Solid 4Q
Mon, 06 Feb 2012 13:22:36 GMTGreece Worries Sink U.S. Stock Futures, Humana and Hasbro Earnings in Focus
Mon, 06 Feb 2012 13:21:58 GMTThe Curse of Amylin's Diabetes Drug Approval
Mon, 06 Feb 2012 12:07:16 GMTQ4 2011 Amylin Pharmaceuticals, Inc. Earnings Release - After Market Close
Mon, 06 Feb 2012 11:25:55 GMTThe Zacks Analyst Blog Highlights: Alkermes plc, Elan, Johnson & Johnson, Amylin Pharmaceuticals and Eli Lilly & Company
Mon, 06 Feb 2012 05:01:00 GMTA Complete Checklist For This Week's Big Earnings Announcements
Mon, 06 Feb 2012 00:41:00 GMTWeekly diabetes drug to be made in West Chester
Mon, 06 Feb 2012 00:00:00 GMTHere Are The Key Market Moving Events For Monday, February 6, 2012
News provided by Yahoo! Finance
Home | StockProphet | Top 100 Stocks | New Hot Stock Picks | Sector Analyzer | Industry Analyzer | Member's Area | FAQ | Contact Us | Privacy and Security
(C) Copyright CycleProphet, Inc.  All Rights Reserved.

*Past performance does not guarantee future results. CycleProphet makes no representations or warrants that just because a stock would have made a profit in the past, using CycleProphet buy recommendations or sell recommendations, it will make any profits in the future. It is possible that these same stocks will lose money in the future using the CycleProphet stock recommendations.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither CycleProphet nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the CycleProphet site, a user agrees not to redistribute the information found therein.

thinkorswim, Division of TD AMERITRADE, Inc. and CycleProphet are separate, unaffiliated companies and are not responsible for each other's services and products.